VABYSMO

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VABYSMO (VABYSMO).

How it works

Vabysmo (faricimab) is a bispecific monoclonal antibody that binds to vascular endothelial growth factor-A (VEGF-A) and angiopoietin-2 (Ang-2), inhibiting their activity. By blocking VEGF-A, it reduces endothelial cell proliferation, vascular permeability, and angiogenesis. By inhibiting Ang-2, it stabilizes blood vessels by enhancing pericyte coverage and reducing vascular leakage and inflammation.

What the body does with it

Metabolism	Metabolized by catabolic pathways into small peptides and amino acids; no significant hepatic metabolism.
Excretion	Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Half-life	Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Protein binding	Faricimab is a monoclonal antibody; serum protein binding is not determined as standard for biologics. It is assumed to be highly bound to target antigens (VEGF-A and Ang-2) rather than nonspecific serum proteins.
Volume of Distribution	Volume of distribution: Approximately 3.2 L (based on population PK, typical for antibodies) in the central compartment after intravitreal injection. Not reported in L/kg; value reflects distribution primarily within the eye and systemic circulation.
Bioavailability	Intravitreal injection: 100% bioavailability (administered directly into the vitreous humor). Not applicable to other routes.
Onset of Action	Intravitreal injection: Clinical benefit (improvement in best-corrected visual acuity) observed as early as 4 weeks after first dose.
Duration of Action	Duration of action: Sustained visual and anatomic improvements for up to 16 weeks between doses in phase 3 trials. Dosing interval adjusted based on disease activity, typically every 8, 12, or 16 weeks.

Classification & Brands

Dosing & administration

Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required based on GFR.
Liver impairment	No dose adjustment required based on Child-Pugh classification.
Pediatric use	Safety and efficacy in pediatric patients have not been established.
Geriatric use	No dose adjustment required in elderly patients; clinical studies included patients aged 65 years and older with no overall differences in safety or efficacy observed.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VABYSMO (VABYSMO).

Breastfeeding	No data on presence in human milk, effects on breastfed infant, or milk production. Monoclonal antibodies are excreted in breast milk at low levels likely due to large molecular size. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on infant.
Teratogenic Risk	No human data available; animal studies show no teratogenic effects at supratherapeutic exposures. Based on anti-VEGF mechanism, potential risk of fetal vascular development disruption cannot be excluded. Risk in first trimester unknown; avoid use in pregnancy unless benefit justifies potential risk.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Active ocular or periocular infections","Known hypersensitivity to faricimab or any excipient in the formulation","Active intraocular inflammation (e.g., uveitis)"]

Clinical Precautions

Precautions

["Endophthalmitis and retinal detachments (injection-related)","Intraocular inflammation","Increased intraocular pressure (IOP) within 30 minutes of injection","Thromboembolic events (potential risk, though rare in clinical trials)","Not recommended in patients with active ocular or periocular infections"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

VABYSMO

Clinical safety rating: caution

Comprehensive clinical and safety monograph for VABYSMO (VABYSMO).

How it works

What the body does with it

Metabolism	Metabolized by catabolic pathways into small peptides and amino acids; no significant hepatic metabolism.
Excretion	Renal elimination: Vabysmo (faricimab) is a monoclonal antibody; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion data are available; renal elimination of intact antibody is minimal due to high molecular weight. Biliary/fecal excretion is not a major route.
Half-life	Terminal elimination half-life: approximately 26 days (range 20–36 days) in clinical studies. This supports dosing every 8–16 weeks for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).
Protein binding	Faricimab is a monoclonal antibody; serum protein binding is not determined as standard for biologics. It is assumed to be highly bound to target antigens (VEGF-A and Ang-2) rather than nonspecific serum proteins.
Volume of Distribution	Volume of distribution: Approximately 3.2 L (based on population PK, typical for antibodies) in the central compartment after intravitreal injection. Not reported in L/kg; value reflects distribution primarily within the eye and systemic circulation.
Bioavailability	Intravitreal injection: 100% bioavailability (administered directly into the vitreous humor). Not applicable to other routes.
Onset of Action	Intravitreal injection: Clinical benefit (improvement in best-corrected visual acuity) observed as early as 4 weeks after first dose.
Duration of Action	Duration of action: Sustained visual and anatomic improvements for up to 16 weeks between doses in phase 3 trials. Dosing interval adjusted based on disease activity, typically every 8, 12, or 16 weeks.

Classification & Brands

Dosing & administration

Intravitreal injection, 6 mg (0.05 mL of 120 mg/mL solution) once every 4 weeks (monthly) for 4 doses, then 6 mg every 8 weeks (2 months) thereafter.

Dosage form	INJECTABLE
Renal impairment	No dose adjustment required based on GFR.
Liver impairment	No dose adjustment required based on Child-Pugh classification.
Pediatric use	Safety and efficacy in pediatric patients have not been established.
Geriatric use	No dose adjustment required in elderly patients; clinical studies included patients aged 65 years and older with no overall differences in safety or efficacy observed.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for VABYSMO (VABYSMO).

Breastfeeding	No data on presence in human milk, effects on breastfed infant, or milk production. Monoclonal antibodies are excreted in breast milk at low levels likely due to large molecular size. M/P ratio unknown. Consider developmental and health benefits of breastfeeding along with mother's clinical need and potential adverse effects on infant.
Teratogenic Risk	No human data available; animal studies show no teratogenic effects at supratherapeutic exposures. Based on anti-VEGF mechanism, potential risk of fetal vascular development disruption cannot be excluded. Risk in first trimester unknown; avoid use in pregnancy unless benefit justifies potential risk.

Warnings & precautions

■ FDA Black Box Warning

None

Side Effect Profile

Serious Effects

Absolute Contraindications

["Active ocular or periocular infections","Known hypersensitivity to faricimab or any excipient in the formulation","Active intraocular inflammation (e.g., uveitis)"]